

If you are in any doubt as to any aspect of this circular, or as to the action to be taken, you should consult your stockbroker or other licensed securities dealer, bank manager, solicitor, professional accountant or other professional advisers.

If you have sold or transferred all your shares in **Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.**, you should at once hand this circular, together with the form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



HANGZHOU JIUYUAN GENETIC BIOPHARMACEUTICAL CO., LTD.

杭州九源基因生物醫藥股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2566)

**(1) PROPOSED CHANGES IN USE OF PROCEEDS;
(2) PROPOSED AMENDMENTS TO THE ARTICLES OF
ASSOCIATION;
AND
(3) NOTICE OF THE EXTRAORDINARY GENERAL MEETING**

A notice convening the EGM of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. to be held at 2:30 p.m. on Friday, September 18, 2026 at Conference Room 3, No. 23, Eighth Street, Baiyang Street, Hangzhou City, Qiantang District, Zhejiang Province, PRC is set out on page 13 of this circular. A proxy form for use at the EGM is also enclosed in this circular. Such proxy form is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.china-gene.com).

Shareholders who intend to appoint a proxy to attend the EGM shall complete and return the enclosed proxy form in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the EGM or any adjournment thereof (as the case may be). Completion and return of the proxy form will not preclude Shareholders from attending and voting in person at the EGM or any adjourned meeting thereof if Shareholders so wish.

August 31, 2026

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
NOTICE OF THE EXTRAORDINARY GENERAL MEETING	13

DEFINITIONS

In this circular, unless otherwise defined or the context otherwise requires, the following expressions have the following meanings:

“Articles of Association”	the articles of association of the Company (as amended from time to time)
“Board”	the board of Directors
“Company,” “our Company,” or “the Company”	Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (杭州九源基因生物醫藥股份有限公司) (formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. (杭州九源基因工程股份有限公司)), a limited liability company established under the laws of the PRC on December 31, 1993 and converted into a joint stock company with limited liability on December 5, 2023
“Director(s)”	the director(s) of our Company
“EGM”	the extraordinary general meeting of the Company to be convened and held on Friday, September 18, 2026
“Global Offering”	the offer of H Shares for subscription as described in the prospectus of the Company dated November 20, 2024
“H Share(s)”	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is/are listed on the Main Board of the Stock Exchange and subscribed for and traded in Hong Kong dollars
“HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC
“H Share Full Circulation”	the conversion of the then 136,302,015 unlisted shares of the Company into H Shares, which was completed on May 14, 2026, and the listing of the converted H Shares on the Stock Exchange, which commenced on May 15, 2026

DEFINITIONS

“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Net Proceeds”	the net proceeds from the Global Offering (after deducting the underwriting fees and related listing expenses)
“PRC”	the People’s Republic of China
“Prospectus”	the prospectus of the Company dated November 20, 2024
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	the shareholder(s) of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“%”	per cent

LETTER FROM THE BOARD



HANGZHOU JIUYUAN GENETIC BIOPHARMACEUTICAL CO., LTD.

杭州九源基因生物醫藥股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2566)

Executive Directors:

Mr. Fu Hang

(傅航) (Chairman of the Board and
general manager)

Mr. Zhou Wei (周偉)

Registered Office, Head Office and

Principal Place of Business in the PRC:

No. 23, Eighth Street

Baiyang Street, Qiantang District

Hangzhou, Zhejiang Province

PRC

Non-executive Directors:

Mr. Wu Shihang (吳詩航)

Mr. Albert Esteve Cruella

Mr. Fei Junjie (費俊傑)

Ms. Yan Weiting (嚴瑋婷)

Principal place of business in Hong Kong:

46/F, Hopewell Centre

183 Queen's Road East

Wan Chai

Hong Kong

Independent non-executive Directors:

Dr Mr. Zhou Zhihui (周智慧)

Ms. Ho Mei Yi (何美儀)

Dr. Zhou Demin (周德敏)

Dr. Huang Wenli (黃文禮)

Employee Representative Director:

Mr. Xu Feihu (徐飛虎)

August 31, 2026

To the Shareholders,

Dear Sir or Madam,

- (1) PROPOSED CHANGES IN USE OF PROCEEDS;
(2) PROPOSED AMENDMENTS TO THE ARTICLES OF
ASSOCIATION;
AND
(3) NOTICE OF THE EXTRAORDINARY GENERAL MEETING**

LETTER FROM THE BOARD

I. INTRODUCTION

The Company intends to hold the EGM at 2:30 p.m. on Friday, September 18, 2026 at Conference Room 3, No. 23, Eighth Street, Baiyang Street, Hangzhou City, Qiantang District, Zhejiang Province, PRC. The notice to convene the EGM is set out on page 13 of this circular.

The purpose of this circular is to provide you with details of the resolutions to be proposed to consider and approve at the EGM and provide all the information reasonably required to enable you to make an informed decision on whether to vote for or against or abstain from voting on those resolutions.

II. PROPOSED CHANGES IN USE OF PROCEEDS

Details of the Proposed Changes in Use of Proceeds

After taking into account the Company's current financial position and business plans, the Board resolved to reallocate an aggregate of approximately RMB118.68 million of the unutilized Net Proceeds (the "**Proposed Changes in Use of Proceeds**"). The Net Proceeds amounted to approximately HK\$478.66 million (equivalent to RMB442.28 million). As of June 30, 2026, approximately RMB122.01 million in aggregate had been utilized, and the balance of unutilized Net Proceeds was approximately RMB320.27 million.

As shown below, part of the Net Proceeds remains unutilized due to changes in the progress of the relevant projects and the Company's funding arrangements. The Board has resolved to reallocate an aggregate of approximately RMB118.68 million of the unutilized Net Proceeds, being the sum of (i) RMB95.47 million reallocated to the continued research and development of JY57 and JY54; and (ii) RMB23.22 million reallocated to production line renovation.

LETTER FROM THE BOARD

The breakdown of the Net Proceeds before and after the Proposed Changes in Use of Proceeds is as follows:

Use of Net Proceeds	Original Allocation Amount (HK\$ in million)	Original Allocation Amount (RMB in million) ⁽¹⁾	Amount Unutilized Before Reallocation (RMB in million)	Amount Unutilized After Reallocation (RMB in million)	Reallocation Amount (RMB in million)	Updated Timeframe
For continued research and development of our selected product candidates in our strategically focused therapeutic areas	192.57	177.93	128.13	147.21	19.08	December 2029
For continued research and development of our selected metabolic disease product candidates that are currently at preclinical stage, pending the initiation of clinical trials, or pending NDA	99.85	92.26	57.61	100.66	43.05	December 2029
– JY29-2 (Jiyoutai 吉優泰 [®])	12.92	11.94	10.45	–	(10.45)	/
– JY29-2 (Jikeqin 吉可親 [®])	38.77	35.83	21.26	–	(21.26)	/
– JY29-2 (oral)	25.18	23.26	22.70	2.00	(20.70)	December 2029
– JY57	–	–	–	33.97	33.97	December 2029
– JY54	22.98	21.23	3.19	64.69	61.50	December 2029
For continued research and development of our selected orthopedic product candidates that are currently at preclinical stage	43.56	40.25	31.53	31.53	–	December 2029
– JY23	29.68	27.42	18.73	18.73	–	December 2029
– JY41	13.88	12.83	12.80	12.80	–	December 2029
For continued research and development of our selected oncology product candidates that are currently at preclinical stage or pending the initiation of clinical trials	49.16	45.42	38.99	15.03	(23.97)	December 2029
– JY47	26.57	24.55	23.97	–	(23.97)	/
– JY43-2	22.59	20.88	15.03	15.03	–	December 2029

LETTER FROM THE BOARD

Use of Net Proceeds	Original Allocation Amount (HK\$ in million)	Original Allocation Amount (RMB in million) ⁽¹⁾	Amount Unutilized Before Reallocation (RMB in million)	Amount Unutilized After Reallocation (RMB in million)	Reallocation Amount (RMB in million)	Updated Timeframe
For marketing and commercialization of our existing and near-commercialized products	143.07	132.20	100.32	100.32	–	December 2029
For expansion of our sales and marketing team	119.23	110.17	83.28	83.28	–	December 2029
For intensifying market publicity and development of our marketed product	23.84	22.02	17.03	17.03	–	December 2029
For strategic collaboration to enrich our product portfolio in our targeted therapeutic areas	47.67	44.05	44.05	44.05	–	December 2029
For our manufacturing system to construct new production lines, and to upgrade and further automate our existing production facilities to prepare for the potential increase in demand for our products and the launch of new products	47.67	44.05	42.30	23.22	(19.08)	December 2029
For new cell line preparation workshop for JY47 and JY43-2	34.46	31.84	31.21	–	(31.21)	/
For JY29-2 APIs production line	7.18	6.63	5.51	–	(5.51)	/
For new external packaging production line for JY29-2	2.87	2.65	2.65	–	(2.65)	/
For new Pilot Workshop for JY23	1.91	1.77	1.77	–	(1.77)	/
For renovation of Yinuojia Filling Machine	0.96	0.88	0.88	–	(0.88)	/
For new Internal Packaging Production Line for Guyoudao	0.24	0.22	0.22	–	(0.22)	/
For installation of Jijufen Batch Scale-up Equipment	0.05	0.04	0.04	–	(0.04)	/

LETTER FROM THE BOARD

	Original Allocation Amount (HK\$ in million)	Original Allocation Amount (RMB in million) ⁽¹⁾	Amount Unutilized Before Reallocation (RMB in million)	Amount Unutilized After Reallocation (RMB in million)	Reallocation Amount (RMB in million)	Updated Timeframe
Use of Net Proceeds						
For JG-23 B product capacity expansion and medical device center relocation	–	–	–	2.40	2.40	December 2029
For new process and new workshop construction for semaglutide APIs for JG-27	–	–	–	2.82	2.82	December 2029
For semaglutide equipment renovation	–	–	–	18.00	18.00	December 2029
For working capital and other general corporate purposes	<u>47.67</u>	<u>44.05</u>	<u>5.47</u>	<u>5.47</u>	<u>–</u>	December 2029
Total	<u>478.66</u>	<u>442.28</u>	<u>320.27</u>	<u>320.27</u>		

Note:

- (1) The Net Proceeds were received in HKD and translated to RMB at the rate of HKD1.00 to RMB0.924 quoted by the People's Bank of China for foreign exchange transactions prevailing on November 28, 2024.

LETTER FROM THE BOARD

Reasons for the Proposed Changes in Use of Proceeds

The proposed use of the Net Proceeds as disclosed in the Prospectus was prepared based on the Company's estimates of the market conditions as of the date of the Prospectus. The Board continuously reviews the use of the unutilized Net Proceeds and, where appropriate, considers adjusting the allocation to ensure the most effective use of the Net Proceeds. After taking into account the Company's current financial position and business plans, the Board has resolved to adjust the use of the unutilized Net Proceeds as follows:

- The balance of the Net Proceeds originally allocated to the "continued research and development of our selected product candidates in strategically focused therapeutic areas" is approximately RMB76.39 million. As JY29-2 is approaching the NDA approval, a limited amount of additional funding is expected to be required for such project. In addition, following the Company's internal assessment, the development of JY47 has been put on hold in order to optimize the allocation of the Company's research and development resources, taking into account factors including the market prospects, development progress and expected resource requirements of its product pipelines. As metabolic diseases remain one of the Company's key strategic therapeutic areas, JY54 (for diabetes and weight management) and JY57 (for metabolic dysfunction-associated steatohepatitis) are important product candidates in the Company's pipeline. The Company expects these product candidates to require additional funding to support their continued development and accelerate the progress of their clinical development, with a view to further strengthen the Company's product pipeline in the metabolic disease therapeutic area. Accordingly, it is proposed that RMB95.47 million out of the Net Proceeds (being the aggregation of the above RMB76.39 million and RMB19.08 million as described below) be reallocated to JY54 and JY57 to better align the use of the Net Proceeds with the Company's current development strategy, project progress and funding needs.
- The balance of the Net Proceeds originally allocated to the "manufacturing system to construct new production lines, and to upgrade and further automate our existing production facilities to prepare for the potential increase in demand for our products and the launch of new products" is approximately RMB42.30 million. As the originally planned production lines and renovation projects have already been financed using the Company's own funds, the relevant Net Proceeds are no longer required for such purposes. Meanwhile, in light of the Company's evolving production needs, the Company's existing production capacity for Guyoudao® and semaglutide active pharmaceutical ingredients may not satisfy the anticipated market demand over the next several years. The Company commenced the relevant capacity expansion projects in 2024 and has been progressing

LETTER FROM THE BOARD

as planned, which are expected to require additional funding. Accordingly, it is proposed that RMB23.22 million out of the relevant Net Proceeds be reallocated to the expansion of the JG-23 B production facilities and relocation of the medical device center, the construction of new production facilities for JG-27 semaglutide active pharmaceutical ingredients, and the upgrading of semaglutide production equipment, in order to support the continued implementation of these projects and further enhance the Company's production capacity. The remaining RMB19.08 million will be reallocated to JY54 and JY57.

Based on the progress schedules of the respective projects, the expected timelines for the utilization of the remaining unutilized Net Proceeds have all been extended to December 2029. Apart from the above changes, there are no other changes to the use of the unutilized Net Proceeds.

The Proposed Changes in Use of Proceeds is based on a prudent assessment of the Company's actual operating conditions and funding needs, and will help optimize resource allocation and enhance the efficiency of the use of the Net Proceeds. The Board considers that the Proposed Changes in Use of Proceeds will not have any material adverse impact on the Company's existing business and operations and is in the best interests of the Company and its Shareholders as a whole.

An ordinary resolution is being proposed at the EGM to consider and approve the Proposed Changes in Use of Proceeds.

LETTER FROM THE BOARD

III. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

To reflect the proposed changes in business scope and the changes in the Company's equity structure following the completion of the H Share Full Circulation, the Board proposed to make the amendments to the Articles of Association (the "**Proposed Amendments to the Articles of Association**"), details of which are set out below.

Articles of Association Before the Amendment	Articles of Association After the Amendment
Article 16 The scope of business of the Company, as registered in accordance with the laws, covers: Licensed items: Pharmaceutical production (excluding the application of the concocting technology such as steaming, frying, roasting and calcining of Chinese medicine tablets and the production of confidential prescription products of proprietary Chinese medicines); the operation of Class III medical devices; import and export of pharmaceutical products; road freight transport (excluding dangerous goods); manufacturing of pharmaceutical excipients; sales of pharmaceutical excipients (For items that require approval in accordance with the law, business activities may only be carried out after approval by relevant departments. The specific business items are subject to the result of the approval). General items: Sales of Class I medical devices; sales of Class II medical devices; technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; property management; import and export of goods; health consulting services (excluding diagnosis and treatment services); (Except for those items which are subject to approval in accordance with the law, business activities are to be carried out independently in accordance with the law on the basis of the business licence); sales of additive manufacturing equipment. The following items are restricted to be operated by branches only: Licensed items: The production of Class III medical devices (For items that require approval in accordance with the law, business activities may only be carried out after approval by relevant departments. The specific business items are subject to the result of the approval). The Company may adjust its scope of business in accordance with changes in domestic and overseas markets, business development and its own capabilities, and shall complete the relevant business registration procedures for changes in accordance with the requirements.	Article 16 The scope of business of the Company, as registered in accordance with the laws, covers: Licensed items: Pharmaceutical production (excluding the application of the concocting technology such as steaming, frying, roasting and calcining of Chinese medicine tablets and the production of confidential prescription products of proprietary Chinese medicines); the operation of Class III medical devices; import and export of pharmaceutical products; road freight transport (excluding dangerous goods); manufacturing of pharmaceutical excipients; sales of pharmaceutical excipients (For items that require approval in accordance with the law, business activities may only be carried out after approval by relevant departments. The specific business items are subject to the result of the approval); <u>food sales, food sales (pre-packaged food only), online food sales (pre-packaged food only)</u>; General items: Sales of Class I medical devices; sales of Class II medical devices; technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; property management; import and export of goods; health consulting services (excluding diagnosis and treatment services); (Except for those items which are subject to approval in accordance with the law, business activities are to be carried out independently in accordance with the law on the basis of the business licence); sales of additive manufacturing equipment. The following items are restricted to be operated by branches only: Licensed items: The production of Class III medical devices (For items that require approval in accordance with the law, business activities may only be carried out after approval by relevant departments. The specific business items are subject to the result of the approval). The Company may adjust its scope of business in accordance with changes in domestic and overseas markets, business development and its own capabilities, and shall complete the relevant business registration procedures for changes in accordance with the requirements.

LETTER FROM THE BOARD

Articles of Association Before the Amendment	Articles of Association After the Amendment
Article 20 The Company's current equity structure: 245,398,800 ordinary shares, of which 105,302,015 shares are held by domestic shareholders, 31,000,000 shares are held by overseas unlisted foreign shareholders and are 109,096,785 shares held by holders of H Shares.	Article 20 The Company's current equity structure: 245,398,800 ordinary shares, of which <u>245,398,800 shares are</u> held by holders of H Shares.

A special resolution is being proposed at the EGM to consider and approve the Proposed Amendments to the Articles of Association.

IV. NOTICE OF THE EXTRAORDINARY GENERAL MEETING

The EGM will be held at 2:30 p.m. on Friday, September 18, 2026 at Conference Room 3, No. 23, Eighth Street, Baiyang Street, Hangzhou City, Qiantang District, Zhejiang Province, PRC. The notice convening the EGM is set out on page 13 of this circular. The above documents and the proxy of form for use at the EGM are published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.china-gene.com).

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, no Shareholder has a material interest in, and would be required to abstain from voting in respect of, the resolutions to be proposed at the EGM.

For the purpose of determining the Shareholders' eligibility to attend and vote at the EGM (and any adjourned meeting thereof), the register of members of the Company will be closed from Tuesday, September 15, 2026 to Friday, September 18, 2026, both days inclusive, during which period no transfer of H Shares will be registered. The record date for the purpose of ascertaining the eligibility of the holders of H Shares to attend and vote at the EGM is on Friday, September 18, 2026. In order to be eligible to attend and vote at the forthcoming EGM, holders of H Shares must lodge all completed transfer documents accompanied by the relevant share certificates with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong on or before 4:30 p.m. on Monday, September 14, 2026.

Shareholders who intend to appoint a proxy to attend the EGM are required to complete and return the form of proxy to Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong in accordance with the instructions printed thereon as soon as possible and in any event not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof should you so wish.

LETTER FROM THE BOARD

V. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, the resolutions set out in the notice of the EGM will be taken by poll. The poll results will be announced by the Company after the EGM in the manner prescribed under Rule 13.39(5) of the Listing Rules.

VI. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein misleading.

VII. RECOMMENDATIONS

The Directors consider that the proposed resolutions set out in the notice of the EGM and the other matters contained in the notice of EGM are in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend Shareholders to vote in favor of the relevant resolutions to be proposed at the EGM.

By order of the Board
**Hangzhou Jiuyuan Genetic
Biopharmaceutical Co., Ltd.**
杭州九源基因生物醫藥股份有限公司
FU Hang
*Executive Director, Chairman of the Board and
General Manager*

NOTICE OF THE EXTRAORDINARY GENERAL MEETING



HANGZHOU JIUYUAN GENETIC BIOPHARMACEUTICAL CO., LTD.

杭州九源基因生物醫藥股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2566)

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the extraordinary general meeting (the “EGM”) of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the “Company”) will be held at Conference Room 3, No. 23, Eighth Street, Baiyang Street, Hangzhou City, Qiantang District, Zhejiang Province, PRC on Friday, September 18, 2026 at 2:30 p.m. for the purposes of considering and, if thought fit, approving the following resolutions. In this notice, unless the context otherwise requires, terms used herein shall have the same meanings as defined in the Company’s circular dated August 31, 2026.

ORDINARY RESOLUTION

1. To consider and approve the Proposed Changes in Use of Proceeds.

SPECIAL RESOLUTION

2. To consider and approve the Proposed Amendments to the Articles of Association.

By order of the Board
**Hangzhou Jiuyuan Genetic
Biopharmaceutical Co., Ltd.**
杭州九源基因生物醫藥股份有限公司

FU Hang
*Executive Director, Chairman of the Board and
General Manager*

Hangzhou, the PRC, August 31, 2026

As of the date of this notice, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀), Dr. Zhou Demin (周德敏) and Dr. Huang Wenli (黃文禮) as independent non-executive directors; and (iv) Mr. Xu Feihu (徐飛虎) as an employee representative director.

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

Notes:

1. For further details of resolutions, please refer to the circular of the Company dated August 31, 2026.
2. All resolutions at the EGM will be taken by poll pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The results of the poll will be published on the websites of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (www.hkexnews.hk) and the Company (www.china-gene.com) in accordance with the Listing Rules.
3. All Shareholders are eligible for attending the EGM. Any Shareholder entitled to attend and vote at the EGM convened by the above notice is entitled to appoint a proxy or more than one proxy to attend the EGM and vote instead of him/her. A proxy need not be a Shareholder. If more than one proxy is appointed, the number of H Shares in respect of which each such proxy so appointed must be specified in the relevant proxy form. Every Shareholder present in person or by proxy shall be entitled to one vote for each H Share held by him/her.
4. In order to be valid, the proxy form together with the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy thereof, must be completed and returned to the Company’s H Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong (for the holders of H Shares) not less than 24 hours before the time appointed for the EGM. Completion and return of the proxy form will not preclude a Shareholder from attending and voting at the EGM or any adjourned meeting thereof should he/she so wish.
5. For the purpose of determining the Shareholders’ eligibility to attend and vote at the EGM (and any adjourned meeting thereof), the register of members of the Company will be closed from Tuesday, September 15, 2026 to Friday, September 18, 2026, both days inclusive, during which period no transfer of H Shares will be registered. The record date for the purpose of ascertaining the eligibility of the holders of H Shares to attend and vote at the EGM is on Friday, September 18, 2026. In order to be eligible to attend and vote at the forthcoming EGM, holders of H Shares must lodge all completed transfer documents accompanied by the relevant share certificates with the Company’s H Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong on or before 4:30 p.m. on Monday, September 14, 2026.
6. The EGM is expected to take no more than half a day. Shareholders who attend the EGM (in person or by proxy) shall bear their own travelling and accommodation expenses.
7. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalf. A proxy need not be a Shareholder.
8. Shareholders or their proxies shall provide their identification documents when attending the EGM. In case of a corporate Shareholder, its proxy or other person authorized to attend the meeting with a resolution passed by the board of directors or other decision-making authorities of such corporate Shareholder, should provide a copy of such resolution.
9. In case of joint holders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s) and for this purpose seniority will be determined by the order in which the names stand on the register of members of the Company in respect of the joint shareholding.

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

10. The contact of the Company:

Address: Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
No. 23, Eighth Street
Baiyang Street, Qiantang District
Hangzhou, Zhejiang Province
PRC
Postal Code: 310018

Contact Person: Mr. Hu Rong (胡榕)

Email: hurong@china-gene.com